It’s a volatile day for biotech stocks Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and Depomed Inc (NASDAQ:DEPO) today, with both on a sharp descent …
Depomed Inc (NASDAQ:DEPO) investors are having a rough day after the drug maker posted weak third-quarter results and lowered its guidance. DEPO reported $110.
Depomed Inc (NASDAQ:DEPO) reported financial results and highlighted operational achievements for the quarter ended September 30, 2016. “Although our third quarter revenues increased by …
Depomed Inc (NASDAQ:DEPO) announced that it has entered into a settlement agreement with its second largest shareholder, Starboard Value LP (together with its affiliates, …
Depomed Inc (NASDAQ:DEPO) announced that Judge Claire C. Cecchi of the United States District Court for the District of New Jersey has ruled in …
In pre-market trading, Depomed Inc (NASDAQ:DEPO) shares rose over 15% to $24.49 following a Reuters article indicating that the drug maker may be exploring a sale, and could begin …
Depomed Inc (NASDAQ:DEPO) announced the presentation of clinical data from 10 trials and studies involving NUCYNTA® ER, Gralise® Lazanda® and a novel, first-in-class investigational …
Analyst Ken Trbovich from Janney Montgomery reiterated his buy rating for Depomed Inc (NASDAQ:DEPO) with a price target of $28, marking a 43% …
Piper Jaffray analyst David Amsellem downgrades Depomed Inc (NASDAQ:DEPO) from Overweight to Neutral with a a price target of $18.00.
UBS analyst Ami Fadia has downgraded DepoMed Inc (NASDAQ:DEPO) from Buy to Hold. The analyst sees risk in management’s 2016 sales guidance of …